"Korean pharma draws attention, open innovation will heat up
By Son, Hyung Min | translator Hong, Ji Yeon
24.11.22 05:50:38
가나다라
0
MOHW-KHIDI held the '2024 Global Open Innovation Week' on November 20
Global pharmaceuticals with patents of products set to expire actively invest in R&D in various fields
Implied on collaborating with Asian companies…developing ADC·obesity·radiopharmaceuticals
▲The Ministry of Health and Welfare (MOHW) and the Korea Health Industry Development Institute (KHIDI) held the
Global pharmaceutical companies continue to invest in research & development (R&D) to overcome patent expiration. Industry experts have said that open innovation between global pharmaceutical companies and Korean pharmaceutical companies will be fired up, enabling collaborations in various diseases. According to industry sources on November 21, the Ministry of Health and Welfare (MOHW) and the Korea Health Industry Development Institute (KHIDI) held the '2024 Global Open Innovation Week' on November 20 at El Tower, Seoul. Representatives from various global pharmaceutical companies, including BMS, Novo Nordisk, and Takeda, attended the event and presented about R&D approaches and collaboration opportu
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)